(Q36993242)

English

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

scientific article published on 11 September 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus (English)

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

lupus erythematosus

1 reference

based on heuristic

inferred from title

systemic lupus erythematosus

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

7

object named as

Joan T Merrill

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Ellen M Ginzler

3

object named as

Ellen M Ginzler

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

author name string

Richard Furie

1

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

William Stohl

2

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Michael Becker

4

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Nilamadhab Mishra

5

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Winn Chatham

6

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Arthur Weinstein

8

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

W Joseph McCune

9

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

John Zhong

10

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Wendy Cai

11

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

William Freimuth

12

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Belimumab Study Group

13

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

publication date

11 September 2008

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Arthritis Research and Therapy

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

10

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

5

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

R109

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

29 September 2017

New approaches of B-cell-directed therapy: beyond rituximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

29 September 2017

Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

29 September 2017

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

29 September 2017

BCMA is essential for the survival of long-lived bone marrow plasma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

29 September 2017

Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

29 September 2017

B lymphocytes and systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

29 September 2017

B cell depletion therapy in systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

29 September 2017

Effective B cell depletion with rituximab in the treatment of autoimmune diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

29 September 2017

BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

29 September 2017

DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

29 September 2017

Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

29 September 2017

BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

29 September 2017

Rituximab: the first monoclonal antibody approved for the treatment of lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

29 September 2017

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

29 September 2017

Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

29 September 2017

Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

29 September 2017

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

29 September 2017

Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

29 September 2017

Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

29 September 2017

The central and multiple roles of B cells in lupus pathogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

29 September 2017

BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

29 September 2017

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

29 September 2017

The CD40 antigen and its ligand

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

29 September 2017

Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

27 June 2018

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

27 June 2018

G-CSF-stimulated neutrophils are a prominent source of functional BLyS

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

27 June 2018

A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

27 June 2018

The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

4 September 2018

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

4 September 2018

B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

4 September 2018

Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

4 September 2018

Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

4 September 2018

Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

20 October 2018

Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592791

4 December 2018

Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/18786258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Classification and definition of major flares in SLE clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/18786258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18786258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/18786258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function

1 reference

https://pubmed.ncbi.nlm.nih.gov/18786258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera

1 reference

https://pubmed.ncbi.nlm.nih.gov/18786258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18786258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/18786258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response

1 reference

https://pubmed.ncbi.nlm.nih.gov/18786258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36993242&oldid=2199703352"